New Issues of Barclays' India ETN Halted
Barclays suspends sale of India ETN for the second time since 2007.
Barclays suspends sale of India ETN for the second time since 2007.
On Dec. 9, India's financial regulator Securities and Exchange Board of India banned Barclays Bank from issuing offshore derivative instruments, due to the bank's improper disclosure regarding the trading activities of these financial instruments. Following SEBI's notice, Barclays announced that it has halted the further sale and issuance of its iPath MSCI India Index ETN but will continue to redeem notes upon shareholder request.
This is the second time Barclays has suspended the sale of this ETN since it was created in December 2006. Back in 2007, sales activities related to this ETN were halted due to uncertainties regarding new SEBI regulations. In the month following the sale suspension, INP traded at an average premium of 15.8% to net asset value, due to a supply shortage. When normal trading activities were reinstated, INP's average premium returned to a range of 1% to 2% in 2008.
Following this current suspension, INP closed at a 2% premium to NAV on Dec. 11, which is higher than recent levels-- in 2009, INP traded at an average 0.63% discount to NAV. While we do not expect Barclays to shut down the fund, we highlight that when Deutsche Bank shut down its PowerShares DB Crude Oil Double Long ETN in September this year, shareholders were returned the cash value of the NAV, and not the market value (see details here). Should Barclays decide to close INP, we would recommend investors sell the fund before the redemption and try to capture a little additional return through the market price premium.
Like many other emerging markets, India's stock market has performed very strongly this year-- INP's year-to-date return is almost 100%. Other India-specific ETF options include--PowerShares India Portfolio (PIN), WisdomTree India Earnings Fund (EPI), and newly launched iShares S&P India Nifty Fifty Index Fund (INDY). There are also two closed-end funds available--Blackstone Group's India Fund (IFN) and Morgan Stanley India Investment Fund (IIF). And finally, there are about a dozen or so India-specific mutual funds available as well.
ETFInvestor Newsletter | ||||
Let our new newsletter, Morningstar ETFInvestor, help you navigate the exciting and new world of exchange-traded funds. Each issue includes recommendations for commonsense ETF investing, | ETF spotlights, and critical data on 150 top ETFs. This one-year subscription consists of 12 monthly issues. Learn more. | |||
$159.00 for 12 Print Issues | $149 for 12 PDF Issues | |||
Transparency is how we protect the integrity of our work and keep empowering investors to achieve their goals and dreams. And we have unwavering standards for how we keep that integrity intact, from our research and data to our policies on content and your personal data.
We’d like to share more about how we work and what drives our day-to-day business.
We sell different types of products and services to both investment professionals
and individual investors. These products and services are usually sold through
license agreements or subscriptions. Our investment management business generates
asset-based fees, which are calculated as a percentage of assets under management.
We also sell both admissions and sponsorship packages for our investment conferences
and advertising on our websites and newsletters.
How we use your information depends on the product and service that you use and your relationship with us. We may use it to:
To learn more about how we handle and protect your data, visit our privacy center.
Maintaining independence and editorial freedom is essential to our mission of empowering investor success. We provide a platform for our authors to report on investments fairly, accurately, and from the investor’s point of view. We also respect individual opinions––they represent the unvarnished thinking of our people and exacting analysis of our research processes. Our authors can publish views that we may or may not agree with, but they show their work, distinguish facts from opinions, and make sure their analysis is clear and in no way misleading or deceptive.
To further protect the integrity of our editorial content, we keep a strict separation between our sales teams and authors to remove any pressure or influence on our analyses and research.
Read our editorial policy to learn more about our process.